TORONTO, June 07, 2018 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”)
(TSX:EDT) (OTCQX:EDTXF), a Phase III company developing the first treatment for patients with septic shock guided by a companion
diagnostic, today announced that at the annual meeting (the “Meeting”) of shareholders of the Corporation
(“Shareholders”) that was held late last week, all five nominees for the board were elected, the voting results of
which are as follows:
|
Director |
Number and percentage of common shares of the
Corporation (“Shares”) represented in person or by
proxy and entitled to vote at the Meeting that were voted FOR |
Number and percentage of Shares represented
in person or by proxy and entitled to vote at the
Meeting that were WITHELD from voting |
| Paul
M. Walker |
125,296,622
(99.40%) |
754,354 (0.60%) |
|
Anthony Bihl III |
125,316,438 (99.42%) |
734,538 (0.58%) |
| Kevin
Giese |
125,300,888 (99.40%) |
750,088 (0.60%) |
|
Guillermo Herrera |
125,319,388 (99.42%) |
731,588 (0.58%) |
|
William Stevens |
125,300,464 (99.40%) |
750,512 (0.60%) |
Full details of the foregoing are contained in the Report of Voting Results for the Meeting which has been filed on Sedar at
www.Sedar.com.
About Spectral Medical Inc.
Spectral is a Phase III company seeking U.S. Food and Drug Administration (“FDA”) approval for
its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic
hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin
Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.
PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more
than 150,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for
PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 350,000 patients
are diagnosed with severe sepsis and septic shock in North America each year. Spectral is listed on the Toronto Stock Exchange
under the symbol EDT. For more information please visit www.spectraldx.com.
Forward-looking statements
Information in this news release that is not current or historical factual information may constitute
forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the
future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as
well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of
preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and
uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion
of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting
of necessary approvals by regulatory authorities, general economic, market and business conditions, as well as other risks and
uncertainties which are more fully described in Spectral’s Annual Information Form dated March 28, 2018, and in other filings of
Spectral with securities and regulatory authorities which are available at www.sedar.com. There is no guarantee that Spectral will
obtain the FDA approval of PMX in the United States. Spectral does not undertake any obligation to update forward-looking
statements should these assumptions change. Nothing in this document should be construed as either an offer to sell or a
solicitation to buy or sell Spectral securities.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this
statement.
For further information, please contact:
